Synergistic combination of azithromycin and sulfadiazine for treatment of toxoplasmosis in mice.
Experiments were performed in vivo in a mouse model of acute toxoplasmosis to evaluate the effectiveness of the combination azithromycin/sulfadiazine. Azithromycin alone or sulfadiazine alone, at doses that did not provide any protection against death due to toxoplasmosis, were remarkably and significantly synergistic against murine toxoplasmosis when administered in combination.
Araujo
F G
FG
Research Institute, Palo Alto Medical Foundation, California 94301.
Lin
T
T
Remington
J S
JS
D000818:Animals; D017963:Azithromycin; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D051379:Mice; D013411:Sulfadiazine / Q000627:therapeutic use*; D014122:Toxoplasma / Q000302:isolation & purification; D014124:Toxoplasmosis, Animal / Q000188:drug therapy*
D013411:Sulfadiazine; D004917:Erythromycin; D017963:Azithromycin